Acute Myocardial Infarction
Conditions
Keywords
Paclitaxel, stent, Acute infarction, Systolic time elevation
Brief summary
Study objective is the evaluation of safety and efficacy at 9 months of combination treatment of bare metal Stent plus Paclitaxel Eluting Balloon vs bare metal stent (conventional treatment) in patients with acute myocardial infarction with systolic time elevation of less than 12 hours of evolution.
Detailed description
This is a multicenter, prospective, randomized, open study After the permeabilization of the clinical event responsible artery and the insertion of a bare metal stent, patients will be randomized in a 1:1 ratio to one of the following treatment groups: Group 1: post-dilatation with a paclitaxel eluting balloon (Pantera Lux ®) Group 2: no post-dilatation Patients (or their legal representative) must sign the consent before randomization. After surgery, patients will be treated with dual antiplatelet therapy (aspirin plus clopidogrel) for at least one month to group 2 patients; and at least 3 months in those who are also treated with the paclitaxel eluting balloon (group 1). Aspirin is prescribed indefinitely according to the usual practice in these patients. Patients will be monitored 30 days after surgery, at 6 and 12 months, and the ninth month (in which patient will receive an angiographic control). The primary efficacy endpoint is late lumen loss (PLT) comparing it value during surgery and control angiography at 9 months This study will involve patients over 18 years olds with systolic time elevation myocardial infarction, or new left bundle branch block or posterior AMI (ECG) that occur within 12 hours of onset of symptoms to treatment by primary angioplasty. They include a total of 220 patients.
Interventions
After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
DEVICEBare metal Stent
After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
Sponsors
Effice Servicios Para la Investigacion S.L.
Francisco Javier Goicolea
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged less than 18 years. * Acute myocardial infarction (AMI) within 12 hours of evolution (from the onset of symptoms) systolic time elevation of at least 1 mm (recorded in two or more contiguous leads), new left bundle branch block, or true posterior infarction. * Patients candidates for primary angioplasty as medical criteria * Written informed consent according to International Conference on Harmonization / Guide Clinical Practice and local legislation, obtained before any study procedure. * Diameter vascular coronary artery to treat between 2 mm and 4 mm. * Patients with 90-100% stenosis.
Exclusion criteria
* Patients who refuse to participate in the study * Cardiogenic shock (defined as systolic blood pressure less than 80 mm Hg for more than 30 minutes or need for vasopressors or intra-aortic balloon counterpulsation) * Concomitant diseases associated with a life expectancy of less than one year * Angiographic variables: * Trunk unprotected * Branching (side branch greater than 2.5 mm) * Sinus tachycardia segment elevation myocardial infarction thrombosis secondary to stent * If more than one stent to treat a single segment (overlapping stents). * Patient candidate for surgical revascularization within 30 days * Stenosis of greater than 30 mm in length (corresponding with the ball longer available) * Reference vessel diameter less than 2.5 mm and greater than 4 mm (larger ball) * More severe stenosis in the same artery in which is expected to be addressed in the next 9 months * Women at childbearing age, where there is the possibility of pregnancy during the first year of follow-up, or nursing. * Any clinical condition, which in the opinion of the investigator, is considered clinically significant as to participate in the study. * Subjects who are participating in any study drug or medical. * Individuals who show inability to follow instructions or help during the course of the study. * Bleeding diathesis or other disorders such as gastrointestinal ulceration or cerebral circulatory disorders, restricting the use of treatments platelet aggregation inhibitors and anticoagulants. * Patients with an ejection fraction \<30% (if known). * Allergy or hypersensitivity to paclitaxel intolerance, or compounds structurally related to the Butyryl tri-n-hexyl citrate (BTHC) matrix of administration. * Severe allergy to contrast media. * Coronary artery spasm in the absence of significant stenosis. * Cases in which is indicated bypass surgery within 30 days after infarction.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Late Luminal Loss | 1 year | Loss measured in millimeters of late luminal space in vessels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy | 1 year | Efficacy: angiography restenosis, minimal luminal diameter, ischemia directed target vessel revascularization (TVR), MACE (death, infarction, TVR) |
| Safety | 1 year | Safety: MACE/ month, at 6 months and 12 months (death, re-infarction, acute cardiovascular disease, hemorrhagy and/or stent thrombosis). |
Countries
Spain
Outcome results
None listed